Core Viewpoint - The article discusses the financial performance and technological advancements of Chongqing Xishan Technology Co., Ltd., highlighting a decline in revenue and profit while emphasizing its innovative capabilities in the medical device sector [2][3][6]. Financial Data - In 2024, the company achieved operating revenue of 336 million yuan, a year-on-year decrease of 6.74% [6] - The net profit attributable to shareholders was 98.67 million yuan, down 15.92% year-on-year [6] - The net profit after deducting non-recurring items was 71.71 million yuan, a decline of 22.45% year-on-year [6] - The asset-liability ratio stood at 8.35%, an increase of 1.56 percentage points compared to the same period last year [6] - The diluted earnings per share were 1.97 yuan, a decrease of 22.13% year-on-year [6] - The net cash inflow from operating activities was 39.47 million yuan, down 42.03% year-on-year, primarily due to increased expenditures on material procurement, employee salaries, taxes, and R&D [6] About Xishan Technology - Chongqing Xishan Technology Co., Ltd. was established in December 1999 and went public on the Sci-Tech Innovation Board in June 2023 [3] - The company is a national high-tech enterprise engaged in the R&D, manufacturing, sales, and service of digital minimally invasive surgical equipment and consumables [3] Products and Business - The surgical power devices cover various clinical departments including neurosurgery, ENT, orthopedics, and breast surgery, with a diverse range of product models to meet most surgical needs [7] - The endoscope systems include 4K ultra-high-definition endoscopic imaging systems applicable in multiple surgical fields, providing clear and naturally colored surgical field images [7] - Energy surgical equipment includes ultrasonic bone tissue surgical devices, plasma surgical devices, and high-frequency surgical devices, which work in conjunction with surgical power devices and endoscope systems to form comprehensive solutions [7] Technology and Innovation - The company has established three provincial and ministerial-level research platforms and has undertaken multiple national and provincial research projects [7] - As of April 30, 2024, the company has applied for over 1,200 patents, with more than 100 domestic and foreign invention patents granted [7] - The company has led the drafting of 8 national medical device industry standards and is the drafting unit for the national pharmaceutical industry standard for electric bone tissue surgical devices [7] - Core technologies include optical system design, optical processing, ISP image processing technology, and FPGA algorithm implementation technology, with innovations that enhance surgical precision, safety, and efficiency [7]